Sunitinib Treatment for Metastatic Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
; : 349-353, 2013.
Article
em En
| WPRIM
| ID: wpr-78966
Biblioteca responsável:
WPRO
ABSTRACT
Von Hippel-Lindau (VHL) disease is an autosomal dominant disease that produces a variety of tumors and cysts in the central nervous system and visceral organs, including renal cell carcinoma (RCC). RCC in patients with VHL disease does not frequently metastasize, therefore, the response to treatment and prognosis of metastatic RCC developed in patients with VHL disease has not been reported. Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor with antiangiogenic and antitumor activity. Here, we report on four patients with metastatic RCC in VHL disease who received sunitinib and achieved partial responses that have lasted for a prolonged period of time.
Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Prognóstico
/
Proteínas Tirosina Quinases
/
Carcinoma de Células Renais
/
Sistema Nervoso Central
/
Doença de von Hippel-Lindau
/
Metástase Neoplásica
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article